Oncolytics Biotech (ONCY +5%) moves up after announcing its Phase 2 interim data from clinical...

|By:, SA News Editor

Oncolytics Biotech (ONCY +5%) moves up after announcing its Phase 2 interim data from clinical trials, using an intravenous administration of its pancreatic cancer drug Reolysin in combination with other drugs, successfully reached its primary endpoint.